Oxygen Of The Saccharide Radical Bonded Directly To A Nonsaccharide Hetero Ring Or A Polycyclo Ring System Which Contains A Nonsaccharide Hetero Ring Patents (Class 514/27)
  • Patent number: 10813868
    Abstract: The invention provides a method for improving the volume of hair which comprises the following steps: (i) treating the hair by topical application of a composition comprising from 1 to 25 wt % of one or more glucosamine salts; (ii) shaping the treated hair; (iii) allowing the composition to remain in contact with the shaped hair before drying. Advantageously the method of the invention does not require the breakage of the hair disulfide bonds, does not require the use of high temperature heated implements such as straightening irons, and can be accomplished by a consumer without intervention of a professional hairdresser.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: October 27, 2020
    Assignee: Conopco, Inc.
    Inventors: Ezat Khoshdel, Prem Kumar Cheyalazhagan Paul
  • Patent number: 10806744
    Abstract: Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. According to Node et al. (Cardiovascular diabetology, 8, 23 (2009)), repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: October 20, 2020
    Assignee: Conopco, Inc.
    Inventors: Mark Ian Fowler, Huijun Wang
  • Patent number: 10744113
    Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: August 18, 2020
    Assignee: OSTEONEUROGEN INC.
    Inventors: Byung Soo Youn, Han Soo Kim, Ho Sup Yoon
  • Patent number: 10646489
    Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: May 12, 2020
    Assignee: NuSirt Sciences, Inc.
    Inventors: Michael Zemel, Antje Bruckbauer, Brooke Baggett
  • Patent number: 10639403
    Abstract: The present disclosure relates to a coated implantable medical device, comprising: a base layer comprising mTOR inhibitor, and at least one biodegradable polymer; a middle layer comprising mTOR inhibitor, and at least one biodegradable polymer; and a top layer selected from the group consisting of hydrophilic polymer, and combination of hydrophilic polymer and antioxidant, wherein the total mTOR inhibitor concentration over the medical device is in the range of 0.7 to 3.00 ?g/mm2. The present disclosure further relates to a method of preparing a coated implantable medical device.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: May 5, 2020
    Assignee: SAHAJANAND MEDICAL TECHNOLOGIES PRIVATE LIMITED
    Inventors: Ankur Jaykumar Raval, Chhaya Babubhai Engineer, Vandana Bharat Patravale
  • Patent number: 10639381
    Abstract: Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L1-(A-L2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 5, 2020
    Inventors: Andrew G. Myers, Daniel J. Smaltz, Andreas Schumacher
  • Patent number: 10583145
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 10, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 10576057
    Abstract: The present invention relates to a composition for preventing and treating muscle diseases or improving muscular function, containing, as an active ingredient, at least one selected from the group consisting of morusin, kuwanon G, and a Mori Cortex Radicis extract. The Mori Cortex Radicis extract, morusin, or kuwanon G, according to the present invention, has an effect of remarkably enhancing muscular function by increasing the expression of p-mTOR protein involved in muscular protein synthesis, inhibiting the expression of mRNAs of MuRF-1 and atrogin-1 involved in muscular protein degradation, and increasing the expression of mRNAs of MyoD and myogenin involved in muscular differentiation. In addition, the present invention is a natural product so as to be used safely without side effects, thereby being usable in drugs, food, or cosmetics.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: March 3, 2020
    Assignee: NEWTREE CO., LTD.
    Inventors: Jae-Kwan Hwang, Mi-Bo Kim, Changhee Kim, Doun Kim, Heechul Chung
  • Patent number: 10555982
    Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A, Baicalein, Chrysin, and their glucuronides Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactives.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 11, 2020
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Beena Bhat, Anurag Pande
  • Patent number: 10537601
    Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 21, 2020
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Jing-Rong Wang, Zhi-Hong Jiang, Qi-Tong Feng, Guo-Yuan Zhu, Wei-Na Gao, Zifeng Yang, Nanshan Zhong
  • Patent number: 10493021
    Abstract: The present invention provides stable antioxidant cosmetic formulations for topical use comprising green tea extract in combination with additional active compounds having the surprising ability to exert antioxidant effect on the skin, the use stable antioxidant cosmetic formulations, as well as a method for reducing and/or preventing oxidative stress in keratinous tissues.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 3, 2019
    Assignee: NATURA COSMÉTICOS S.A.
    Inventors: Ana Paula Pedroso De Oliveira, Cristiane Calvo De Santi, Gabriela Placoná Diniz, Jenny Chu Yan Ling Okuda, Juliana Carvalhães Lago, Kelen Fabíola Arroteia
  • Patent number: 10420756
    Abstract: The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 24, 2019
    Assignee: SEN-JAM PHARMACEUTICAL LLC.
    Inventors: Jacqueline M. Iversen, James M. Iversen
  • Patent number: 10383842
    Abstract: A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, and ICAM-1 inhibitor which each also down regulate the immune response. The composition may further include a permeation enhancer.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 20, 2019
    Assignee: GLOBAL BIOLIFE INC.
    Inventor: Daryl Thompson
  • Patent number: 10376465
    Abstract: The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 13, 2019
    Assignee: Pulmatrix Operating Company, Inc.
    Inventors: Michael M. Lipp, Jean C. Sung
  • Patent number: 10350230
    Abstract: Disclosed is a use of albiflorin or a pharmaceutically acceptable salt for the prevention and/or treatment of irritable bowel syndrome. The experimental results demonstrate that the prevention, remission and/or treatment of irritable bowel syndrome with albiflorin or a pharmaceutically acceptable salt has significant effects and few side effects. This is a preparation derived from a natural plant for the safe, effective and multi-targeted prevention, remission and/or treatment of irritable bowel syndrome.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: July 16, 2019
    Inventor: Zuoguang Zhang
  • Patent number: 10335356
    Abstract: The present invention discloses a use of neohesperidin or a neohesperidin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of neohesperidin or a neohesperidin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using neohesperidin. The skin microcirculation of the present invention is preferably eye skin microcirculation.
    Type: Grant
    Filed: November 25, 2011
    Date of Patent: July 2, 2019
    Assignee: Natural Medicine Institute of Zhejiang Yangshengtang Co., Ltd.
    Inventors: Liu Hu, Hongying Lan
  • Patent number: 10328183
    Abstract: Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 25, 2019
    Assignee: COOK MEDICAL TECHNOLOGIES LLC
    Inventors: John Jackson, Lindsay Stuart Machan, Kevin Letchford
  • Patent number: 10285976
    Abstract: Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone. Methods for treating autoimmune diabetes, multiple sclerosis and/or autoimmune demyelination, including administering to the subject a composition having a compound in an amount effective to inhibit hyaluronan synthesis in a mammalian subject, are also described.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: May 14, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON
    Inventors: Paul L. Bollyky, Nadine Nagy, Thomas Wight, Hedwich F. Kuipers
  • Patent number: 10286068
    Abstract: A vaccine composition is disclosed that contains a vaccine antigen and a neutrophil inhibitor in amounts effective to promote an IgA response to the antigen in a subject. Also disclosed is a method for enhancing immune response to a vaccine antigen in a subject that involves co-administering to the subject the vaccine antigen and an adjuvant composition comprising a neutrophil inhibitor in an amount effective to promote an IgA response to the vaccine antigen in the subject.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 14, 2019
    Assignee: Ohio State Innovation Foundation
    Inventor: Prosper Boyaka
  • Patent number: 10278949
    Abstract: A biotechnology process that employs membrane technology for obtaining an extract rich in tannins of ellagic acid from blackberries (Rubus spp.) and from other fruits that contain these compounds, as well as to the extract obtained using this method. The method is essentially based on baromembrane technologies that allow mechanical separation and effective fractionation between the polyphenol compounds, by interactions between the physico-chemical properties thereof, the material of the membrane and the molar mass of same, thereby allowing enrichment of a fraction of the natural extract with ellagic acid tannins and modification of the content thereof in terms of anthocyanins and other compounds such as sugars and acids.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 7, 2019
    Assignees: UNIVERSIDAD DE COSTA RICA, CENTRO INTERNACIONAL DE COOPERACION EN INVESTIGACION AGRICOLA PARA EL DESARROLLO, CIRAD, CENTRO INTERNACIONAL DE ESTUDIOS SUPERIORES EN CIENCIAS AGRONOMICAS, SUPAGRO
    Inventors: Oscar Gerardo Acosta Montoya, Ana Mercedes Perez Carvajal, Manuel Dornier, Fabrice Vaillant
  • Patent number: 10272099
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: April 30, 2019
    Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois.
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
  • Patent number: 10196417
    Abstract: A baicalin magnesium compound and methods for preparing and extracting the same. The method for preparing the baicalin magnesium compound includes steps of preparation of a baicalin suspension, preparation of a magnesium ion-containing suspension, reaction and drying. The method for extracting the baicalin magnesium compound includes steps of pretreatment of macroporous resin, extraction, adsorption and elution, concentration and drying and purification. The methods restores the baicalin to the original form as found in radix scutellariae, and the baicalin magnesium compound may be used as a substitute for the baicalin in pharmaceutical applications. As compared to the baicalin, the baicalin magnesium has a greatly increased solubility, faster adsorption rate and higher oral bioavailability. The baicalin magnesium compound may also be easily formulated as a water-soluble injection or a powder injection.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: February 5, 2019
    Assignee: CHENGDE MEDCIAL UNIVERSITY
    Inventors: Cuizhe Liu, Zhixuan Wang, Ceyu Miao, Liyan Liu, Hefei Xue, Xigang Liu, Wenshan Du, Yixin Liu, Lin Zhang, Xiaoxia Mao, Jinjun Liu, Guiqin Zhao
  • Patent number: 10155003
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: December 18, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 10149877
    Abstract: The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: December 11, 2018
    Assignee: INDENA S.P.A.
    Inventor: Ezio Bombardelli
  • Patent number: 10137136
    Abstract: In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: November 27, 2018
    Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Christopher M. Adams, Steven D. Kunkel, Michael Welsh
  • Patent number: 10131727
    Abstract: The present invention relates to a process for the development of a highly efficient solid state matrix by the activation of acrylate based polymer resin having specialized functional groups with 1,1-Carboxyl diimidazole for immobilizing biologically active macromeloecules such as oxidases, in particular plant oxidases and the most preferred being tea polyphenol oxidase through indirect covalent bonding/cross linking on such activated polymer resin support, are thermally stable, gives very high number of turnovers in vitro (“n” times) with tea substrate forming exclusive product Theaflavins without any loss of biological activity and leaving the product remaining in vitro with adherence to matrix rendering the matrix safe towards product poisoning and subsequent partial or complete loss of biological activity of the matrix bound enzyme system and thus well adapted to and well suited biorectors based on such systems.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: November 20, 2018
    Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Harsh Pratap Singh, Kapil Sharma
  • Patent number: 10123992
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 13, 2018
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 10111854
    Abstract: The present invention relates to novel series of amine-containing flavonoids and compositions containing the compounds, as well as the synthesis and the use of the same. The invention also relates to methods of treatment and prevention of diseases, in particular, parasitic infections including Leishmaniasis, comprising administration of the compounds.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: October 30, 2018
    Assignee: The Hong Kong Polytechnic University
    Inventors: Larry Ming-Cheung Chow, Tak Hang William Chan, Kin-Fai Chan, Iris Lai King Wong, Wing-Yiu Kan
  • Patent number: 10098838
    Abstract: The invention relates to water-soluble granules for preparing a drinkable solution, in particular for preventing or treating symptoms associated with mild to moderate chronic venous insufficiency of the lower extremities, containing at least 20 percent by weight of a concentrated extract of red wine leaves, and to a ready-to-use packaging unit comprising one or more portion sachets which contain the granules according to the invention.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 16, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sandra Sauerland, Sonja Heigenhauser, Uwe Scheuring, Oliver Timm
  • Patent number: 10076513
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: September 18, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
  • Patent number: 10058579
    Abstract: A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the Cinnamonum aromaticum, Cinnamonum verum or Cinnamonum burmannii plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: August 28, 2018
    Assignee: IN Ingredients, Inc.
    Inventors: Peter J. Miller, Tim Romero, Bolin Qin, Augustin T. Romero
  • Patent number: 10016421
    Abstract: Disclosed are methods whereby an effective amount of a HDAC6 inhibitor is used to activate a subjects T-cell response to tumor or tumor vaccine. Methods of using HDAC6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: July 10, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Eduardo M. Sotomayor, Alejandro V. Villagra
  • Patent number: 9987214
    Abstract: A composition having a pH in the range of from 3 to 8.5, comprising: (a) in the range of from 0.1% to <10% w/w (based on the total weight of the composition) of a stock solution comprising a mixture of bioflavonoids and fruit acids or salts thereof; (b) sodium hyaluronate; and (c) water; and, optionally, (d) a pharmaceutically acceptable carrier therefor; wherein the sodium hyaluronate has an average molecular weight of between 800,000 and 4,000,000.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 5, 2018
    Assignees: Oraldent Limited, Ricerfarma S.R.L.
    Inventors: Ian Ripley, Howard Thomas
  • Patent number: 9956242
    Abstract: The pharmaceutical composition of the present invention, which comprises spinosin or a spinosin-containing herbal extract, is a composition for preventing and treating cognitive function disorders, and can effectively improve memory and learning ability, and effectively treat and prevent cognitive function disorders such as dementia and amnesia.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: May 1, 2018
    Assignees: MINISTRY OF FOOD AND DRUG SAFETY, DAE HWA PHARMA, CO., LTD.
    Inventors: Jong Hoon Ryu, Hyung Eun Lee, Sam Sik Kang, Ju Sun Kim, So Young Lee, Do Hoon Kim, Dong Sup Kim, Seung Hee Kim
  • Patent number: 9925152
    Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: March 27, 2018
    Inventor: Lanny Leo Johnson
  • Patent number: 9895390
    Abstract: The technology described herein is directed to the treatment of cancer, e.g. methods and assays relating to selecting and administering a chemotherapy with or without an EZH2 inhibitor.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: February 20, 2018
    Assignee: Children's Medical Center Corporation
    Inventors: Christine M. Fillmore, Carla F. Kim
  • Patent number: 9849151
    Abstract: A Salacia composition described herein significantly reduces appetite, activates Hormone Sensitive Lipase, and manages a healthy lipid profile through inhibition of HMG-CoA Reductase enzyme. Salacia compositions described herein include of at least 12% of polyphenols, 2% of mangiferin and 1% of 25,26-oxidofriedelane-1,3-dione by weight of the composition in the form of extract. The composition is obtained by continuous solvent extraction, employing non-aqueous food grade solvents. Salacia compositions herein reduce appetite by about 18% of routine diet, when effective amounts are administered to a subject in need thereof. Effective management of a healthy lipid profile is thus possible with synergistic combination of reduction in energy intake, activation of Hormone Sensitive Lipase, and inhibition of HMG-CoA Reductase enzyme responsible for cholesterol metabolism.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: December 26, 2017
    Assignee: OmniActive Health Technologies (Canada) Limited
    Inventors: Jayant Deshpande, Khadija Ghanam, Stephen Ewart, Vijaya Juturu
  • Patent number: 9801850
    Abstract: The present invention provides an epigallocatechin gallate derivative (EGCG derivative) that has excellent safety and antibacterial properties. An epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is used as an antibacterial agent. In the formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of the R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 31, 2017
    Assignee: OSAKA UNIVERSITY
    Inventors: Kunihiro Kaihatsu, Yoshimi Matsumoto
  • Patent number: 9782386
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: October 10, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 9757424
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a glioma. Methods of this invention include administering to a subject in need thereof an effective amount of a first active agent, such as e.g., an angiotensin receptor blocker, an antifungal agent, a bisphosphonate, an oxytocin inhibitor, an interleukin-1 (IL-1) inhibitor, a cyclooxygenase inhibitor, an ?2? voltage-dependent calcium channel (VDCC) inhibitor, a dihydroorotate dehydrogenase inhibitor, a calcium channel blocker, a renal sodium-chloride symporter inhibitor, an a2 adrenergic agonist, a phenothiazine antipsychotic, a calcineurin inhibitor, a 5-HT agonist, an angiotensin-converting enzyme (ACE) inhibitor, a direct rennin inhibitor, or combinations thereof, and a second active agent, which is a chemotherapeutic agent. Compositions for treating or ameliorating the effects of a glioma are also provided.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: September 12, 2017
    Assignee: Biomed Valley Discoveries, Inc.
    Inventors: Reza Halse, Saurabh Saha, Jeffrey James Roix
  • Patent number: 9737515
    Abstract: The present invention relates to compositions and methods for preventing and treating cell proliferation in cancer. More specifically, the present invention relates to compositions and methods for inhibiting tumor growth, and for treating proliferative diseases, particularly colon and breast cancer, with a combined pharmacological approach. Yet more specifically, the compositions for inhibiting tumor growth comprise a combination of: i) a first component which is an ACSL4 inhibitor; and ii) a second component selected from the group consisting of mTOR inhibitor and ER inhibitor.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: August 22, 2017
    Assignee: Consejo Nacional De Investigaciones Cientificas Y Tecnicas (CONICET)
    Inventors: Ernesto Jorge Podesta, Paula Mariana Maloberti, Ulises Daniel Orlando, Melina Andrea Dattilo, Ana Fernanda Castillo, Angela Rosaria Solano
  • Patent number: 9724361
    Abstract: The present invention relates to a pharmaceutical composition for treating liver diseases, containing a narirutin extract of citrus peel extract or narirutin as an active ingredient. The extract or narirutin decreases cholesterol levels and fat levels in liver tissue, and thus can be utilized as a composition or food for preventing and treating liver diseases. In addition, the present invention relates to a method for extracting narirutin from citrus peel, and a method for preparing citrus fermented milk using the same.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 8, 2017
    Assignee: Korea Food Research Institute
    Inventors: In Wook Choi, Yong Kon Park, Yoon Sook Kim, Hee Don Choi, Ho Young Park
  • Patent number: 9688711
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 27, 2017
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Adam Aaron Goldblum, Martin Sheringham Linsell, Paola Dozzo, Heinz Ernst Moser, Darin James Hildebrandt, Micah James Gliedt
  • Patent number: 9609884
    Abstract: Anti-fatigue agents containing dioxabicyclo[3.3.0]octane derivatives such as sesamin which is an ingredient contained in sesame, as well as pharmaceutical compositions and physiologically functional foods that contain such anti-fatigue agents are disclosed. These compounds can safely be administered to humans and animals alike and hence allow for continued ingestion while proving effective in promoting an improvement of stamina, an increase of body strength, a relief of fatigue, and recovery from fatigue.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: April 4, 2017
    Assignee: Suntory Holdings Limited
    Inventors: Yoshiko Ono, Kayo Saito, Norifumi Tateishi, Akifumi Maeda
  • Patent number: 9610276
    Abstract: Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, HbA1c, blood pressure and total cholesterol.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: April 4, 2017
    Assignee: KGK Synergize, Inc.
    Inventor: Najla Guthrie
  • Patent number: 9603862
    Abstract: The invention provides a method of increasing a deacetylase activity of SIRT5 by contacting SIRT5 with an agent that binds SIRT5 and reduces the Km of SIRT5 for a substrate, thereby increasing the deacetylase activity of SIRT5. The invention also provides a method for treating a urea cycle disorder in a mammal, as well as a method of assaying a sirtuin modulator.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: March 28, 2017
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony Sauve, Yana Cen
  • Patent number: 9562037
    Abstract: The present invention relates to novel series of amine-containing flavonoids and compositions containing the compounds, as well as the synthesis and the use of the same. The invention also relates to methods of treatment and prevention of diseases, in particular, parasitic infections including Leishmaniasis, comprising administration of the compounds.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: February 7, 2017
    Assignee: The Hong Kong Polytechnic University
    Inventors: Larry Ming-Cheung Chow, William Tak Hang Chan, Kin-Fai Chan, Iris Lai King Wong, Wing-Yiu Kan
  • Patent number: 9549883
    Abstract: Cosmetic antiperspirants for nonaerosol use, having a content of methanesulfonic acid and/or at least one physiologically acceptable salt of methanesulfonic acid, which exhibit less textile staining than known antiperspirants.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: January 24, 2017
    Assignee: Henkel AG & Co. KGaA
    Inventors: Bernhard Banowski, Marcus Claas
  • Patent number: 9498413
    Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: November 22, 2016
    Inventor: Lanny Leo Johnson
  • Patent number: RE47741
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R11 and R12 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: November 26, 2019
    Assignee: Achaogen, Inc.
    Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell